It would be the first new pill to treat uncomplicated UTIs in 20 years, GSK said.
The drug, called gepotidacin, could become the first new oral antibiotic for uncomplicated UTIs in more than two decades, according to the company.
GSK's drug was tested in uncomplicated UTIs, which are restricted to the the bladder and urethra and are generally less serious than complicated UTIs.
On Thursday, GSK said two studies enrolled over 3,000 patients with uncomplicated UTIs.
GSK, on the other hand, paid $66 million in September to license another antibiotic program being tested to treat complicated UTIs.